<?xml version="1.0" encoding="UTF-8" ?><!-- Generated on Wed, 29 Apr 2026 09:15:01 -0400--><rss version="2.0">
    <channel>
        <title>Oncogenuity, Inc. () Press Releases</title>
        <link>https://www.oncogenuity.com/investors/press-releases/rss</link>
        <description>Please specify a description for this RSS Feed</description>
        <language>en-us</language>
                                            <image>
                <url>https://d1io3yog0oux5.cloudfront.net/_454c730063104ecb66d5e3ea2c6bf2f4/oncogenuity/logo.png</url>
                <title>Oncogenuity, Inc. Logo</title>
                <link>https://www.oncogenuity.com</link>
            </image>
                <generator>Equisolve Investor Relations Suite</generator>
        
                            <item>
                <title><![CDATA[Fortress Biotech Announces Exclusive Worldwide License Agreement With Columbia University to Develop Novel Oligonucleotide Platform for the Treatment of Genetically Driven Cancers]]></title>
                <description><![CDATA[]]></description>
                <link></link>
                <pubDate>Fri, 08 May 20 00:00:00 -0400</pubDate>
                <guid isPermalink="true"></guid>
                                                                            </item>
            </channel>
</rss>